BPC 157 5mg + GHK-CU 35mg + TB500 10mg

Important Note

This page is informational and does not authorize use. Peptify clients should complete assessment, disclose medications and health history, and follow the clinician-approved plan only.

Do not start, stop, combine, or change a protocol based only on website content.
Emergency symptoms require urgent medical care, not a website or routine follow-up message.

Quickstart Highlights

GLOW is a research three-peptide blend — GHK-Cu, TB-500 (a Thymosin Beta-4 fragment) and BPC-157 — supplied together in a single 70 mg vial. Each component has been studied separately for tissue-repair-related activity in preclinical and cell models[1][5]. This page outlines a once-daily subcutaneous approach for the combined vial. The idea that the three act “synergistically” is a marketing hypothesis, not validated in any human trial; none of the three peptides is FDA-approved, and the blend is presented for research and educational use only.

Add 3.0 mL bacteriostatic water to the one combined 70 mg vial → ~23.3 mg/mL total blend (1 unit ≈ 233 mcg total).
2,330 mcg (2.33 mg) total blend once daily for 4 weeks, then a 2–4 week break before any repeat cycle.
At ~23.3 mg/mL, 1 unit ≈ 233 mcg total; the daily 2,330 mcg dose is 10 units (0.10 mL) on a U-100 syringe.
Lyophilized: store at −20 °C (−4 °F); once reconstituted, refrigerate at 2–8 °C (35.6–46.4 °F) and do not freeze the solution.
Important: Start with the Prep & Injection Guide — it covers the preparation and safety basics every protocol on this site assumes.

Dosing & Reconstitution Guide

A single practical dilution with accurate once-daily dosing, step by step

Standard Approach (3 mL = ~23.3 mg/mL total blend)

Phase / Week(s)	Dose & Frequency	Volume (U-100 units / mL)
Weeks 1–4	2,330 mcg total blend (1× daily)	10 units (0.10 mL)
Weeks 5–6/8	Off (no injections)	—

Reconstitute: Add 3.0 mL bacteriostatic water to the combined 70 mg vial → final concentration ~23.3 mg/mL total blend.
Typical daily dose: 2,330 mcg (2.33 mg) total blend once daily for 4 weeks, then 2–4 weeks off.
Easy measuring: At ~23.3 mg/mL, 1 unit ≈ 233 mcg total on a U-100 syringe. The daily 2,330 mcg dose is 10 units (0.10 mL); units = total mcg ÷ 233.
Storage: Lyophilized: store at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) and do not freeze the mixed solution.
Frequency: one subcutaneous injection each day at a fixed 2,330 mcg total-blend dose for 4 weeks, followed by a 2–4 week off period before any repeat cycle[3][4]. This schedule and the split between the three peptides come from the product’s own materials, not from approved human dosing.
Per-component split (inferred): the page does not state how many mg of each peptide are loaded in the 70 mg vial. Applying the product’s stated 5:1:1 ratio to each 2,330 mcg dose implies roughly 1.67 mg GHK-Cu + 0.33 mg TB-500 + 0.33 mg BPC-157 per injection. These are inferred from the ratio, not confirmed vial contents, and they sum to ~2.36 mg versus the 2.33 mg stated (rounding).

Reconstitution Steps

Draw 3.0 mL of bacteriostatic water into a sterile syringe.

Release it slowly down the vial’s inner wall to limit foaming.
Swirl or roll gently until fully dissolved — don’t shake.
Label with the date and concentration, then refrigerate at 2–8 °C (35.6–46.4 °F), shielded from light.
At 23.3 mg/mL the daily dose reads at 10 units (0.10 mL); for a small volume like this, a 30- or 50-unit insulin syringe improves readability. Avoid freezing the reconstituted solution, since freeze–thaw can denature the peptides.
Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

Supplies Needed

Quantities below assume a 4-week course of once-daily injections at the standard 2,330 mcg total-blend dose.

One 70 mg combined vial covers the full 4-week (28-day) daily protocol at standard dosing.
4 weeks (28 days): 1 vial
Per injection: 1 syringe
4 weeks (once daily): 28 syringes
Use 3.0 mL per 70 mg vial for reconstitution.
4 weeks (1 vial): 3 mL → 1 bottle
One for the vial stopper + one for the injection site each day.
Per injection: 2 swabs
4 weeks (once daily): 56 swabs → 1 box (100-count)

Protocol Overview

A concise summary of the once-daily regimen, drawn from commonly cited reference protocols.

▪Goal: Combine three repair-associated peptides (GHK-Cu, TB-500, BPC-157) aimed at tissue repair, angiogenesis and inflammation — effects reported only in preclinical/cell models, with the 3-peptide synergy unvalidated in humans[5][6].
▪Schedule: Daily subcutaneous injections for 4 weeks, then a 2–4 week off period before any repeat cycle.
▪Daily Dose: 2,330 mcg (2.33 mg) total blend once daily = 10 units (0.10 mL).
▪Reconstitution: 3.0 mL bacteriostatic water per 70 mg vial gives ~23.3 mg/mL total blend (1 unit ≈ 233 mcg).
▪Storage: Keep the dry vial frozen at −20 °C (−4 °F); once mixed, refrigerate at 2–8 °C and do not freeze the solution.

Dosing Protocol

A fixed-dose daily approach based on the product’s own materials.

▪Dose: 2,330 mcg total blend once daily (10 units / 0.10 mL); units = total mcg ÷ 233.
▪Per-injection split (inferred): at the stated 5:1:1 ratio, ~1.67 mg GHK-Cu + 0.33 mg TB-500 + 0.33 mg BPC-157 — inferred, not confirmed vial contents.
▪Hold: Keep the dose constant across all 4 weeks rather than titrating.
▪Cycle Length: 4 weeks on, then 2–4 weeks off before any repeat cycle.
▪Timing: Inject at a consistent time each day and rotate injection sites systematically.

Storage Instructions

Correct storage is what preserves the peptide’s stability and activity.

▪Lyophilized: Hold the dry vial at −20 °C (−4 °F) in dry, dark conditions and limit moisture exposure[7].
▪Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F) and use within about 28 days; do not freeze the mixed solution, as freezing can denature peptides[8].
▪Handling: Let frozen vials warm to room temperature before opening so condensation won’t form, and keep the solution clear of heat and direct light.
▪Freeze–thaw: Avoid repeated freeze–thaw cycles of the reconstituted solution.

Important Notes

Practical points that keep daily administration safe and consistent.

▪Sterile technique: Use a fresh sterile U-100 insulin syringe each time and drop it straight into a puncture-proof sharps container afterward.
▪Site rotation: Move between abdomen, thighs and upper arms to reduce local irritation and lipohypertrophy[9].
▪Slow injection: Push the plunger slowly and pause a few seconds before withdrawing the needle to prevent backflow.
▪Recordkeeping: Log the daily dose, injection site and any observations to keep the protocol consistent.
▪Regulatory note: Both TB-500 and BPC-157 are prohibited by WADA (treat the whole blend as banned for athletes); GHK-Cu, TB-500 and BPC-157 are all unapproved research chemicals, none FDA-approved for human administration[10].

How This Works

GLOW packs three different repair-associated peptides into one 70 mg vial. Each has its own proposed mechanism, drawn almost entirely from cell-culture and animal models — none is established in humans.

GHK-Cu (copper tripeptide): a copper-binding tripeptide studied for roles in collagen synthesis, angiogenesis and anti-inflammatory signalling[1]. Topical GHK-Cu is used as a cosmetic ingredient, but injectable GHK-Cu is not approved.
TB-500 (Thymosin Beta-4 fragment): a synthetic peptide reproducing the active region of Tβ4. Its proposed mechanism centres on G-actin sequestering, cell migration and angiogenesis in preclinical work[5][6]. No completed human efficacy trial of the fragment exists.
BPC-157 (gastric peptide): a synthetic sequence derived from a gastric protein, studied in animals for soft-tissue and tendon repair[11]. Human evidence is anecdotal.
Important caveat: the claim that combining the three produces synergistic repair is a marketing hypothesis — it has never been tested in a human trial, and no clinical data validate the specific 70 mg three-peptide combination.
GHK-Cu, TB-500 and BPC-157 are all unapproved research chemicals — none is FDA-approved (2026 compounding activity is not approval). The blend is presented here for research and educational purposes only.

Lifestyle Factors

Habits that may support recovery alongside the protocol.

▪Nutrition: Keep protein intake adequate to give tissue repair the building blocks it needs.
▪Activity & rest: Pair appropriate movement with real recovery time and avoid overtraining during an injury-recovery phase.
▪Sleep: Aim for 7–9 hours to support the body’s natural repair processes.
▪Stress: Manage stress with evidence-based practices, since it influences overall healing.

Potential Benefits & Side Effects

What preclinical and veterinary literature describe; human evidence is limited and individual results vary.

▪Wound healing (preclinical): Animal studies report faster wound healing and tissue repair via enhanced angiogenesis and cell migration[5][6].
▪Inflammation & fibrosis (preclinical): Thymosin pathways have been linked to reduced inflammation and fibrosis in animal models[11].
▪Tolerability (veterinary): Generally well tolerated in veterinary studies, with occasional mild injection-site reactions.
▪Note on humans: These benefits are not established in humans — no large-scale clinical trials of the TB-500 fragment have been completed[13].
▪Injection-site reactions: Mild redness, tenderness or soreness can occur; rotating sites helps.
▪Unknown long-term profile: Human safety data is limited, so caution and monitoring are advised.
▪Sport restriction: Both TB-500 and BPC-157 are WADA-prohibited, so treat the GLOW blend as banned for athletes.

Injection Technique

General subcutaneous technique, following established clinical best-practice guidance[14][15].

▪Wash your hands well with soap and water.
▪Wipe the vial stopper with an alcohol swab and let it air-dry.
▪Choose a site (abdomen, thigh, or upper arm) and clean it with a fresh alcohol swab, letting it dry fully[15].
▪Draw the intended dose, then check for air bubbles and push any out.
▪Pinch a skinfold at the chosen site between thumb and forefinger.
▪Insert the needle into the pinch at a 45–90-degree angle (use 45 degrees if the fat layer is thin)[14].
▪Skip aspiration for subcutaneous shots — it isn’t needed[14].
▪Press the plunger slowly and steadily until it’s fully down.
▪Wait 5–10 seconds, then pull the needle straight out to prevent leakage.
▪Drop the used syringe straight into a puncture-proof sharps container — never recap a needle.
▪Return the reconstituted vial to the fridge right away.
▪Rotate the injection site each day to prevent irritation and lipohypertrophy[9].
▪Watch the site for excess redness, swelling, or signs of infection.

Recommended Source

For high-purity research peptides, we point researchers to Prime Lab Peptides for the GLOW 70 mg three-peptide blend.

▪Top-rated on Trustpilot: Independently reviewed as the highest-rated peptide lab on Trustpilot — making it the best current source in the USA. Open source
▪Third-party tested: Every batch ships with a Certificate of Analysis (COA) confirming purity and composition.
▪Consistent quality: ISO-aligned manufacturing and handling keep product integrity reliable batch to batch.
▪Cold-chain integrity: Temperature-controlled shipping and storage across the whole fulfilment chain.
▪Research-grade purity: Fit for educational and research use that demands high-quality peptides.
Note: Product availability and specifications subject to change. Verify current product details on supplier website.
Shop at Prime Lab Peptides →

References

Reference-derived details for BPC 157 5mg + GHK-CU 35mg + TB500 10mg.

GLOW (70 mg Vial) Dosage Protocol Open source
1 FASEB Journal Biological activities of thymosin beta-4 mapped to active peptide sequences, including the fragment marketed as TB-500. View Source ↗ Open source
2 Journal of Chromatography A (PubMed) Doping-control analysis of TB-500 as a synthetic thymosin beta-4 fragment in biological samples. View Source ↗ Open source
3 WADA Scientific Research Investigation of TB-500 metabolism, synthesis of its metabolites, and detection limits. View Source ↗ Open source
4 Racing Medication & Testing Consortium Thymosin beta-4 regulatory bulletin covering TB-500 use in equine sports medicine. View Source ↗ Open source
5 Journal of Investigative Dermatology (PubMed) Thymosin beta-4 accelerates wound healing in a preclinical model. View Source ↗ Open source
6 FASEB Journal (PubMed) Active-site mapping of thymosin beta-4 fragments for angiogenesis and cell migration. View Source ↗ Open source
7 Peptide Storage Guide Best practices for storing lyophilized peptides (temperature, humidity and light protection). View Source ↗ Open source
8 Bacteriostatic Water Guidance Bacteriostatic water for injection: multi-dose vial stability and handling. View Source ↗ Open source
9 NCBI Bookshelf Best practices for subcutaneous injection: aseptic technique and site rotation. View Source ↗ Open source
10 WADA Prohibited List Classification of TB-500 as a prohibited substance in competitive sport. View Source ↗ Open source
11 Journal of Investigative Dermatology Thymosin beta-4 wound-healing mechanisms: collagen deposition, angiogenesis and granulation tissue. View Source ↗ Open source
12 Journal of Chromatography B (PubMed) Quantification of TB-500 metabolites and screening of wound-healing activity (prodrug hypothesis). View Source ↗ Open source
13 ClinicalTrials.gov Trial registry for full-length thymosin beta-4 (e.g., dermal and ocular indications); no completed efficacy trials of the TB-500 fragment. View Source ↗ Open source
14 Centers for Disease Control and Prevention (CDC) Subcutaneous injection technique: angle, site and no-aspiration guidance. View Source ↗ Open source
15 Subcutaneous Injection Technique (Patient Education) How to administer a subcutaneous injection: clinical technique guidelines. View Source ↗ Open source
16 Prime Lab Peptides GLOW 70 mg blend (GHK-Cu + TB-500 + BPC-157) product page — purity specifications and certificates of analysis. View Source ↗ Open source